PMID- 35786654
OWN - NLM
STAT- MEDLINE
DCOM- 20220823
LR  - 20220901
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 88
IP  - 4
DP  - 2022
TI  - Association Between Metformin and Alzheimer's Disease: A Systematic Review and 
      Meta-Analysis of Clinical Observational Studies.
PG  - 1311-1323
LID - 10.3233/JAD-220180 [doi]
AB  - BACKGROUND: As one of the widely used drugs for the management of type 2 diabetes 
      mellites (T2DM), metformin is increasingly believed to delay cognitive 
      deterioration and therapeutically for Alzheimer's disease (AD) patients 
      especially those with T2DM. However, studies of the potential neuroprotective 
      effects of metformin in AD patients have reported contradictory results. 
      OBJECTIVE: This study aimed to evaluate the association between metformin and the 
      risk of developing AD. METHODS: We systematically searched the PubMed, EMBASE, 
      Web of Science, Cochrane Central Register of Controlled Trials, and 
      ClinicalTrials.gov databases to identify clinical observational studies on the 
      relationship between AD risk and metformin use published before December 20, 
      2021. Two investigators independently screened records, extracted data, and 
      assessed the quality of the studies. Pooled odds ratios (ORs) and corresponding 
      95% confidence intervals (CIs) were calculated using random-effect models. 
      RESULTS: After screening a total of 1,670 records, we included 10 studies 
      involving 229,110 participants. The meta-analysis showed no significant 
      association between AD incidence and metformin exposure (OR 1.17, 95% CI 
      0.88-1.56, p = 0.291). However, subgroup analysis showed that among Asians, the 
      risk of AD was significantly higher among metformin users than those who did not 
      (OR 1.71, 95% CI 1.24-2.37, p = 0.001). CONCLUSION: The available evidence does 
      not support the idea that metformin reduces risk of AD, and it may, in fact, 
      increase the risk in Asians. Further well-designed randomized controlled trials 
      are required to understand the role played by metformin and other antidiabetic 
      drugs in the prevention of AD and other neurodegenerative diseases.
FAU - Luo, Anling
AU  - Luo A
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, P.R. China.
FAU - Ning, Pingping
AU  - Ning P
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, P.R. China.
FAU - Lu, Haitao
AU  - Lu H
AD  - Department of Neurology, Third People's Hospital of Chengdu, Chengdu, Sichuan 
      Province, P.R. China.
FAU - Huang, Hongyan
AU  - Huang H
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, P.R. China.
FAU - Shen, Qiuyan
AU  - Shen Q
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, P.R. China.
FAU - Zhang, Dan
AU  - Zhang D
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, P.R. China.
FAU - Xu, Fang
AU  - Xu F
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, P.R. China.
FAU - Yang, Li
AU  - Yang L
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, P.R. China.
FAU - Xu, Yanming
AU  - Xu Y
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, P.R. China.
LA  - eng
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - *Alzheimer Disease/chemically induced/drug therapy/epidemiology
MH  - *Diabetes Mellitus, Type 2/chemically induced/complications/drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Metformin/therapeutic use
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - cognitive dysfunction
OT  - meta-analysis
OT  - metformin
EDAT- 2022/07/06 06:00
MHDA- 2022/08/24 06:00
CRDT- 2022/07/05 14:02
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/08/24 06:00 [medline]
PHST- 2022/07/05 14:02 [entrez]
AID - JAD220180 [pii]
AID - 10.3233/JAD-220180 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2022;88(4):1311-1323. doi: 10.3233/JAD-220180.